Given that CD147 is a potential drug target in cancer, our laboratory has developed Licartin, an 131I-labeled antibody against CD147 that has been approved as a new drug for the treatment of primary HCC by the China State Food and Drug Administration (No. S20050039, April 2005). This evidence concerns the gene BSG and hepatocellular carcinoma.